Amgen stock trades at EUR 371.30, 29.0 percent higher year to date

Published on 10/09/2026 at 19:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Amgen stock costs EUR 371.30 on October 9, 2026 after EUR 360.08. Cantor Fitzgerald set a USD 440.00 target from USD 400.00 on October 8, 2026.

Key points in brief

Amgen stock was EUR 371.30 at Lang & Schwarz on October 9, 2026, up 3.12 percent versus the EUR 360.08 prior close.
The Nasdaq price was USD 415.95, with a USD 224.5 billion market capitalization and a 25.85 P/E ratio.
Cantor Fitzgerald raised its target from USD 400.00 to USD 440.00 while maintaining a Neutral rating on October 8, 2026.
Amgen is scheduled to report third-quarter 2026 results on November 3, 2026, after the market close.

Bauhaus-Poster mit geometrischen Formen, Molekülstrukturen und großem Schriftzug BIOTECH in Primärfarben — Amgen Inc. (ISIN US0311621009) inspirierte dieses geometrische Bauhaus-Poster mit dem Sektor-Schriftzug BIOTECH, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) stock was trading at EUR 371.30 at Lang & Schwarz after-hours on October 9, 2026, plus 3.12 percent versus the prior close. The euro quote gives German investors a clear same-day market reference while the US listing remains open.

Price stays below the yearly high

On Nasdaq, Amgen was last at USD 415.95 on October 9, 2026 at 1:25 p.m. ET. The USD 288.00 to USD 447.03 52-week range places the Nasdaq price 6.96 percent below the high, calculated in the same currency.

Trading volume was 793,764 shares against an average volume of 2,739,296 shares on October 9, 2026. That leaves the session volume at 28.98 percent of the stated average, while the primary-market price remained inside the yearly range.

Valuation and analyst target

Amgen's market capitalization was USD 224.5 billion on October 9, 2026, with a P/E ratio of 25.85 and a trailing dividend yield of 2.00 percent. These figures place the company among the largest listed biotechnology groups by equity value.

According to Investing.com on October 8, 2026, Cantor Fitzgerald raised its Amgen target from USD 400.00 to USD 440.00 and maintained a Neutral rating. The USD 440.00 target lies 5.78 percent above the USD 415.95 Nasdaq price.

Comparison with peers

Amgen: plus 3.12 percent, P/E 25.85, market capitalization USD 224.5 billion
Gilead Sciences (NASDAQ, USD): plus 2.82 percent, P/E minus 56.65, market capitalization USD 187.5 billion
Vertex Pharmaceuticals (NASDAQ, USD): plus 1.40 percent, P/E 29.70, market capitalization USD 129.5 billion

Next results date

Gekko identifies November 3, 2026, after the market close, as Amgen's next earnings date. The page lists consensus estimates of USD 5.78 earnings per share and USD 10.05 billion revenue for the third quarter of 2026, giving the calendar date a measurable earnings benchmark.

After-hours price holds above the close

Amgen stock was trading at EUR 371.30 at Lang & Schwarz on October 9, 2026 at 7:21 p.m. CEST, plus 3.12 percent versus the Lang & Schwarz prior close of EUR 360.08 on October 8, 2026. On Nasdaq, the stock was last at USD 415.95 at 1:25 p.m. ET on October 9, 2026.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.